NET ASSET VALUE – 30 September 2025
On the 30 September 2025 Flerie AB's Net Asset Value (NAV) was SEK 3,918 million and NAV per share was SEK 50.58.
| Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Prokarium | 42% | 445 | 5.74 | 11.4% |
| Xspray Pharma | 18% | 441 | 5.69 | 11.3% |
| Empros Pharma | 79% | 204 | 2.64 | 5.2% |
| Atrogi | 44% | 197 | 2.54 | 5.0% |
| KAHR Medical | 35% | 171 | 2.21 | 4.4% |
| Xintela | 59% | 162 | 2.09 | 4.1% |
| Lipum | 57% | 134 | 1.73 | 3.4% |
| Bonsai Biotherapeutics (previously Toleranzia) | 100% | 131 | 1.69 | 3.3% |
| Microbiotica | 10% | 127 | 1.63 | 3.2% |
| Geneos Therapeutics | 12% | 90 | 1.17 | 2.3% |
| AnaCardio | 13% | 79 | 1.02 | 2.0% |
| Mendus | 23% | 78 | 1.01 | 2.0% |
| EpiEndo Pharmaceuticals | 9% | 55 | 0.71 | 1.4% |
| Vitara Biomedical | 11% | 47 | 0.61 | 1.2% |
| Buzzard Pharmaceuticals | 14% | 32 | 0.41 | 0.8% |
| Egetis Therapeutics | 1% | 27 | 0.35 | 0.7% |
| Amarna Therapeutics | 58% | 11 | 0.14 | 0.3% |
| Strike Pharma | 18% | 11 | 0.14 | 0.3% |
| Alder Therapeutics | 30% | 8 | 0.10 | 0.2% |
| Synerkine Pharma | 44% | 0 | 0.00 | 0.0% |
| Sixera Pharma | 35% | 0 | 0.00 | 0.0% |
| Total | 2,450 | 31.63 | 62.5% | |
| Commercial Growth | ||||
| NorthX Biologics | 61% | 202 | 2.61 | 5.2% |
| Symcel | 30% | 192 | 2.48 | 4.9% |
| Chromafora | 30% | 73 | 0.94 | 1.9% |
| Nanologica | 44% | 45 | 0.58 | 1.1% |
| Frontier Biosolutions | 2% | 18 | 0.24 | 0.5% |
| Bohus Biotech | 45% | 0 | 0.00 | 0.0% |
| Total | 530 | 6.84 | 13.5% | |
| Limited Partnerships, total | 106 | 1.37 | 2.7% | |
| Assets related to Portfolio companies | 309 | 3.99 | 7.9% | |
| Other assets and liabilities | 522 | 6.75 | 13.3% | |
| Net Asset Value | 3,918 | 50.58 | 100.0% | |